当前位置： SCI文献检索 > BONE MARROW TRANSPLANTATION期刊下所有文献 > A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation.

A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation.

Abstract：

:We studied the effects of escalating doses of recombinant human IL-1 beta in patients receiving high-dose chemotherapy and ABMT for metastatic breast cancer or malignant melanoma. Sixteen patients received IL-1 beta, 4 to 32 ng/kg/day administered subcutaneously for 7 days beginning 3 h after bone marrow infusion. Three patients at the highest dose level also received G-CSF following completion of IL-1 beta. All patients completed the 7 days of therapy. The majority of patients experienced chills and fever following one or more injections, and seven had severe pain at the injection site. There was one episode of hypotension and one episode of transient confusion at the highest dose level; other significant toxicity was not identified. Recovery of neutrophils to > 0.5 x 10(9)l and platelet transfusion independence occurred at a median of 23 and 22 days, respectively, which was comparable to historical controls. The mean number of bone marrow colony-forming unit granulocyte-macrophage (CFU-GM) per 10(5) mononuclear cells on day +21 post-ABMT was more than twice that of control patients or patients receiving G-CSF or GM-CSF. A linear correlation was found between the dose of IL-1 beta and endogenous concentrations of several cytokines. These patients also displayed significantly higher concentrations of endogenous G-CSF compared to historical controls receiving GM-CSF. While IL-1 beta was moderately toxic and had no effect on recovery of peripheral blood counts after ABMT, the increased number of bone marrow CFU-GM suggests that the addition of G- or GM-CSF to a short course of IL-1 beta may accelerate hematologic recovery.

journal_name

Bone Marrow Transplant

journal_title

Bone marrow transplantation

authors

Elkordy M,Crump M,Vredenburgh JJ,Petros WP,Hussein A,Rubin P,Ross M,Gilbert C,Modlin C,Meisenberg B,Coniglio D,Rabinowitz J,Laughlin M,Kurtzberg J,Peters WP

doi

10.1038/sj.bmt.1700633

subject

Has Abstract

pub_date

1997-02-01 00:00:00

pages

315-22

issue

4

eissn

0268-3369

issn

1476-5365

journal_volume

19

pub_type

临床试验,杂志文章

相关文献

BONE MARROW TRANSPLANTATION文献大全
  • Combined foscarnet -ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation (Hsct).

    abstract：:Thirty two allogeneic bone marrow transplant (BMT) recipients, aged 16-55 (median 35), with CMV antigenemia (= > 5 positive cells) developing at a median interval from BMT of 49 days, were given combined treatment with foscarnet and ganciclovir for 15 days. Maintenance was given with foscarnet and ganciclovir on alter...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Bacigalupo A,Bregante S,Tedone E,Isaza A,Van Lint MT,Moro F,Trespi G,Occhini D,Gualandi F,Lamparelli T,Marmont AM

    更新日期：1996-11-01 00:00:00

  • Early allogeneic blood stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid leukemia.

    abstract：:Two patients with high-risk acute myeloid leukemia (AML) whose bone marrow aspirates showed more than 25% blasts between 2 and 4 weeks after the first induction chemotherapy immediately received modified conditioning therapy with intravenous busulfan at 50% of the usual dose and fludarabine, before hematologic recover...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702819

    authors： Platzbecker U,Thiede C,Freiberg-Richter J,Röllig C,Helwig A,Schäkel U,Mohr B,Schaich M,Ehninger G,Bornhäuser M

    更新日期：2001-03-01 00:00:00

  • The HLA-A*0201-restricted minor histocompatibility antigen HA-1H peptide can also be presented by another HLA-A2 subtype, A*0206.

    abstract：:HA-1(H) is one of the most attractive minor histocompatibility antigens (mHA) as a target for immunotherapy of hematopoietic malignancies, but HLA-A*0201 and HLA-B60 molecules capable of presenting HA-1(H)-derived peptides are less common in eastern Asian populations when compared with Caucasian populations. Therefore...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1705689

    authors： Torikai H,Akatsuka Y,Miyauchi H,Terakura S,Onizuka M,Tsujimura K,Miyamura K,Morishima Y,Kodera Y,Kuzushima K,Takahashi T

    更新日期：2007-07-01 00:00:00

  • Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.

    abstract：:Twenty-nine pediatric allogeneic bone marrow transplant (BMT) recipients, ages 2-17 years, were followed prospectively for cytomegalovirus (CMV) infection. Patients at risk received ganciclovir (GCV) prophylactically at a dose of 5 mg/kg/day i.v., 3 to 5 days per week, until day 100. Surveillance blood and urines were...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：

    authors： Canpolat C,Culbert S,Gardner M,Whimbey E,Tarrand J,Chan KW

    更新日期：1996-04-01 00:00:00

  • Non-radiotherapy conditioning with stem cell transplantation from alternative donors in children with refractory severe aplastic anemia.

    abstract：:Conditioning including total body/lymphoid irradiation is widely used to prevent graft rejection in patients with refractory severe aplastic anemia (SAA) undergoing hemopoietic cell transplantation (HCT) from alternative donors and or after graft manipulation. To reduce regimen-related toxicity we transplanted three c...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704792

    authors： Urban C,Benesch M,Sykora KW,Schwinger W,Lackner H

    更新日期：2005-03-01 00:00:00

  • Reevaluation of the National Institutes of Health criteria for classification and scoring of chronic GVHD.

    abstract：:We used the National Institutes of Health (NIH) criteria for the diagnosis, classification and scoring of chronic GVHD (cGVHD) to reevaluate patients with cGVHD originally diagnosed using classic criteria. We retrieved data from 236 patients diagnosed with cGVHD on the basis of classic criteria. Excluding 20 'liver-al...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2009.320

    authors： Kim DY,Lee JH,Lee JH,Kim SH,Lim SN,Kim SD,Choi Y,Lee YS,Kang YA,Kang SI,Seol M,Ryu SG,Lee KH

    更新日期：2010-07-01 00:00:00

  • Allogeneic peripheral blood stem cell transplantation for hypereosinophilic syndrome with severe cardiac dysfunction.

    abstract：:A 42-year-old male underwent an HLA-matched sibling PBSC transplant for hypereosinophilic syndrome (HES) diagnosed in August 1995. Prior to transplant he experienced progressive cardiac and pulmonary dysfunction with red cell and platelet transfusion dependence despite therapy with hydroxyurea, steroids and interferon...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701783

    authors： Chockalingam A,Jalil A,Shadduck RK,Lister J

    更新日期：1999-05-01 00:00:00

  • Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.

    abstract：:In an effort to reduce the relapse rate after unpurged autologous bone marrow transplantation (ABMT) in patients with acute myeloid leukemia (AML) in first complete remission (CR1), the standard conditioning regimens (cyclophosphamide/busulphan and cyclophosphamide/TBI) were intensified by adding idarubicin. Seventeen...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1701279

    authors： Jerjis S,Roovers E,Muus P,Schaap N,de Witte T

    更新日期：1998-07-01 00:00:00

  • Effects of various antireabsorptive treatments on bone mineral density in hypogonadal young women after allogeneic stem cell transplantation.

    abstract：:Ovarian failure after allogeneic stem cell transplant (allo-SCT) is an important risk factor for development of osteoporosis. We investigated the effects of various antiresorptive treatments in long-term surviving females with ovarian failure after allo-SCT. A total of 60 women with osteoporosis or osteopenia were div...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,随机对照试验

    doi：10.1038/sj.bmt.1705196

    authors： Tauchmanovà L,De Simone G,Musella T,Orio F,Ricci P,Nappi C,Lombardi G,Colao A,Rotoli B,Selleri C

    更新日期：2006-01-01 00:00:00

  • Author Correction: High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI/Cancer Research UK Phase II Study.

    abstract：:In the original version of this article, the mention of 'ifosfamide 1500 mg/m2 days 1-3' should, in fact, read 'ifosfamide 1500 mg/m2 bd days 1-3'. This has now been updated in the original version of the article. ...

    journal_title：Bone marrow transplantation

    pub_type： 已发布勘误

    doi：10.1038/s41409-019-0504-6

    authors： Phillips EH,Lannon MM,Lopes A,Chadwick H,Jones G,Sieniawski M,Davies A,Wood K,Clifton-Hadley L,Smith P,Lawrie A,Chadwick N,Lennard AL

    更新日期：2020-04-01 00:00:00

  • Effect of extended immunosuppressive drug treatment on B cell vs T cell reconstitution in pediatric bone marrow transplant recipients.

    abstract：:Allogeneic bone marrow transplantation (BMT) is an effective therapy for a variety of malignancies and blood disorders, but rarely serves as a frontline treatment because of numerous, potential complications. Important and frequent complications relate to the profound immunosuppression that inevitably occurs during th...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1703185

    authors： D'Costa S,Slobod KS,Benaim E,Bowman L,Cunningham J,Holladay M,Howlett N,Srivastava DK,Hurwitz JL

    更新日期：2001-09-01 00:00:00

  • Prospective pilot trial of calcipotriene as a novel topical treatment for acute skin graft versus host disease.

    abstract：:Skin graft versus host disease (GVHD) can affect quality of life in hematopoietic stem cell transplant recipients. Therapeutic options for steroid-refractory GVHD are limited. We report the first prospective pilot study evaluating the topical vitamin D3 analog Calcipotriene (DOVONEX 0.005% cream) for acute skin GVHD i...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-020-01189-3

    authors： Wallace G,Khandelwal P,Myers KC,Perentesis EMR,Lane A,Teusink-Cross A,Smiley K,Davies SM,Jodele S

    更新日期：2021-01-08 00:00:00

  • Elimination of malignant clonogenic T cells from human bone marrow using chemoimmunoseparation with 2'-deoxycoformycin, deoxyadenosine and an immunotoxin.

    abstract：:Autologous bone marrow transplantation may contribute to the treatment of several types of lymphoreticular malignancies. Recent studies have suggested that a combination of chemoseparation and immunoseparation may be more effective than either modality alone in eliminating malignant cells from human bone marrow. In th...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Montgomery RB,Kurtzberg J,Rhinehardt-Clark A,Haleen A,Ramakrishnan S,Olsen GA,Peters WP,Smith CA,Haynes BF,Houston LL

    更新日期：1990-06-01 00:00:00

  • Comparison of hemorrhagic and ischemic stroke after allogeneic hematopoietic stem cell transplantation.

    abstract：:Stroke is an important complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Nevertheless, few studies have been published to analyzed the occurrence and prognosis of stroke after allo-HSCT. From January 2007 to December 2018 in Peking University People's Hospital, 6449 patients receiv...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-020-0903-8

    authors： Cai X,Fu HX,Mo XD,Wang Y,Zhang YY,Wu J,Han W,Tang FF,Gui RY,Chen H,Chen Y,Zhao P,Yan CH,Wang JZ,Chen YH,Chang YJ,Xu LP,Liu KY,Huang XJ,Zhang XH

    更新日期：2020-11-01 00:00:00

  • Blood and marrow transplantation during the emerging COVID-19 pandemic: the Seattle approach.

    abstract：:On January 20, 2020, the first patient with coronavirus disease 2019 (COVID-19) in the United States of America was diagnosed in Washington state, which subsequently experienced rapidly increasing numbers of COVID-19 cases, hospitalizations, and deaths. This placed the Seattle Blood and Marrow Transplant Program at Fr...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/s41409-020-01068-x

    authors： Ueda Oshima M,Sandmaier BM,Petersdorf E,Flowers ME,Hill GR,Lee SJ,Appelbaum FR,Carpenter PA,Baker KS,Connelly-Smith L,McCool A,Elgar S,Pergam SA,Liu C,Stewart FM,Mielcarek M

    更新日期：2020-09-26 00:00:00

  • Feasibility and timing of unrelated donor identification for patients with ALL.

    abstract：:Patients with relapsed ALL frequently have short duration second or later remissions, leaving only a brief window of time when it is possible to perform BMT. When no sibling donor is available, identifying and unrelated donor in a timely fashion can be difficult while autologous BMT (ABMT) can be performed more quickl...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Davies SM,Ramsay NK,Weisdorf DJ

    更新日期：1996-05-01 00:00:00

  • Transplantation of G-CSF mobilized allogeneic peripheral blood stem cells in rabbits.

    abstract：:Mobilized peripheral blood precursor cells (PBPC) are used with increasing frequency to restore autologous hematopoiesis following high-dose radio-chemotherapy. The success of this method has aroused interest in the use of mobilized PBPC for allogeneic transplants. This approach would eliminate the need for marrow asp...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Gratwohl A,Baldomero H,John L,Gimmi C,Pless M,Tichelli A,Nissen C,Filipowicz A,Speck B

    更新日期：1995-07-01 00:00:00

  • Prophylaxis and treatment of chemo- and radiotherapy-induced oral mucositis - are there new strategies?

    abstract：:Oral mucositis is a major dose-limiting toxic effect of intensive cancer chemotherapy. Oral complications may lead to dose reduction or delay in further cancer treatment. Mucositis can be caused directly by cytotoxic effects and indirectly by sustained neutropenia after cytostatic therapy. An impaired mucosal barrier ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/sj.bmt.1702024

    authors： Karthaus M,Rosenthal C,Ganser A

    更新日期：1999-11-01 00:00:00

  • Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal disease.

    abstract：:We report a patient with pre-existing end-stage renal disease (ESRD) who underwent successful matched related donor allogeneic bone marrow transplantation for AML in second complete remission (CR2) using conditioning with high-dose cyclophosphamide (CY, 60 mg/kg/day x 2) and TBI (165 cGy twice daily x 4 days). The tim...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701646

    authors： Perry JJ,Fleming RA,Rocco MV,Petros WP,Bleyer AJ,Radford JE Jr,Powell BL,Hurd DD

    更新日期：1999-04-01 00:00:00

  • Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation.

    abstract：:Thirty adults with leukemia or lymphoma transplanted with marrow or blood stem cells from 1-antigen mismatched related donors received tacrolimus and minidose methotrexate to prevent acute graft-versus-host disease (GVHD). The group had a median age of 42 years (range 18-56 years). Twenty-seven patients had advanced d...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701983

    authors： Przepiorka D,Khouri I,Ippoliti C,Ueno NT,Mehra R,Körbling M,Giralt S,Gajewski J,Fischer H,Donato M,Cleary K,Claxton D,Chan KW,Braunschweig I,van Besien K,Andersson BS,Anderlini P,Champlin R

    更新日期：1999-10-01 00:00:00

  • Relationship between neurocognitive functioning and medication management ability over the first 6 months following allogeneic stem cell transplantation.

    abstract：:Although neurocognitive impairment has been established as a major issue among cancer survivors, the real-world consequences of this impairment are unclear. This study investigated the relationship between neurocognitive functioning and medication management ability over time among 58 patients treated with allogeneic ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2016.2

    authors： Mayo S,Messner HA,Rourke SB,Howell D,Victor JC,Kuruvilla J,Lipton JH,Gupta V,Kim DD,Piescic C,Breen D,Lambie A,Loach D,Michelis FV,Alam N,Uhm J,McGillis L,Metcalfe K

    更新日期：2016-06-01 00:00:00

  • Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation.

    abstract：:Superiority of single-donor apheresis platelets (SDAP) over pooled platelet concentrates (PPC) transfusions is largely assumed, but unproven. We hypothesized that prophylactic SDAP and PPC transfusions are clinically equivalent after allogeneic hematopoietic stem cell transplants (HSCT). We studied all transfusions ad...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1705751

    authors： Gurkan E,Patah PA,Saliba RM,Ramos CA,Anderson BS,Champlin R,de Lima M,Lichtiger B

    更新日期：2007-09-01 00:00:00

  • Second hematopoietic SCT for leukemia relapsing after myeloablative T cell-depleted transplants does not prolong survival.

    abstract：:Patients with leukemia relapsing after allogeneic hematopoietic SCT have a dismal prognosis. A second SCT offers a further opportunity for cure, but has a high rate of treatment failure. To determine the utility of this option, we analyzed 59 consecutive patients relapsing after a myeloablative HLA-matched sibling T c...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/bmt.2013.39

    authors： McIver ZA,Yin F,Hughes T,Battiwalla M,Ito S,Koklanaris E,Haggerty J,Hensel NF,Barrett AJ

    更新日期：2013-09-01 00:00:00

  • Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.

    abstract：:Filgrastim (r-metHuG-CSF)-mobilized peripheral blood progenitor cells (PBPC) and unstimulated bone marrow (BM) were evaluated and compared for reconstitution after high-dose chemotherapy in patients with relapsed Hodgkin's disease (HD) or non-Hodgkin's lymphoma (NHL) with respect to engraftment, overall and relapse-fr...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1038/sj.bmt.1701941

    authors： Kanteti R,Miller K,McCann J,Roitman D,Morelli J,Hurley C,Berkman E,Schenkein D

    更新日期：1999-09-01 00:00:00

  • Headache, circumoral paresthesia, and facial flushing associated with high-dose carmustine infusion.

    abstract：:We describe seven patients who developed symptoms including severe headache, circumoral paresthesia, and facial flushing during high-dose carmustine (BCNU) infusion as part of the preparative regimen for autologous peripheral blood stem cell (PBSC) transplantation for metastatic breast cancer. Five patients responded ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1700743

    authors： Woo MH,Ippoliti C,Bruton J,Mehra R,Champlin R,Przepiorka D

    更新日期：1997-04-01 00:00:00

  • Circulating progenitors following high-dose sequential (HDS) chemotherapy with G-CSF: short intervals between drug courses severely impair progenitor mobilization.

    abstract：:Sequential administration of high-dose chemotherapy courses possibly allows extensive in vivo purging before circulating progenitor collection for autograft. To evaluate whether progenitor cell mobilization was negatively affected by repeated high-dose chemotherapy courses, we studied 23 lymphoma patients undergoing t...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Tarella C,Caracciolo D,Gavarotti P,Bondesan P,Cherasco C,Omedè P,Bregni M,Siena S,Gianni AM,Pileri A

    更新日期：1995-08-01 00:00:00

  • Correlation of colony-forming cells, long-term culture initiating cells and CD34+ cells in apheresis products from patients mobilized for peripheral blood progenitors with different regimens.

    abstract：:Peripheral blood progenitor cell (PBPC) populations used for transplantation were analyzed for the presence of CD34+ cells, colony-forming cells (initial CFC), and long-term culture initiating cells (LTC-IC) cultured on irradiated stroma for 5 weeks. Thirty-eight leukapheresis products were studied from 11 patients wi...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Bender JG,Lum L,Unverzagt KL,Lee W,Van Epps D,George S,Coon J,Ghalie R,McLeod B,Kaizer H

    更新日期：1994-04-01 00:00:00

  • Caspase-8 polymorphisms result in reduced Alemtuzumab-induced T-cell apoptosis and worse survival after transplantation.

    abstract：:Allo-SCT using unrelated donors is a curative treatment for patients with hematological disorders. The best donor is one matched for 10/10 HLA alleles, however studies have shown an additional survival benefit when considering other genetic factors. It has been shown that a six-nucleotide insertion/deletion polymorphi...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1038/bmt.2014.238

    authors： Shaw BE,Lee F,Krishnamurthy S,Byrne JL,Seedhouse C,Mayor NP,Maldonado-Torres H,Saudemont A,Marsh SG,Madrigal JA,Russell NH

    更新日期：2015-02-01 00:00:00

  • Mobilization of peripheral stem cells with intensive chemotherapy (ICE regimen) and G-CSF in chronic myeloid leukemia.

    abstract：:Seventeen patients with Philadelphia (Ph) chromosome-positive chronic myeloid leukemia (CML) were treated with the ICE regimen plus G-CSF with the aim of mobilizing and collecting Ph-negative peripheral stem cells (PSC) in the setting of an autotransplant program. Fifteen patients had CML in first chronic phase (CP), ...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：

    authors： Boqué C,Petit J,Sarrá J,Cancelas JA,Muñoz J,Español JI,de la Banda E,Aventin A,Berlanga J,Ferrá C,Amill B,Torrico C,Azqueta C,Llucià M,García J,Grañena A

    更新日期：1996-11-01 00:00:00

  • Allogeneic bone marrow transplantation for fucosidosis.

    abstract：:Bone marrow transplantation was performed on an 8-month-old boy who was diagnosed as having fucosidosis following the diagnosis of the disease in his older brother. Although he was asymptomatic and his development was normal, abnomalities were found on an MRI scan prior to transplant. In the absence of a suitable rela...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Vellodi A,Cragg H,Winchester B,Young E,Young J,Downie CJ,Hoare RD,Stocks R,Banerjee GK

    更新日期：1995-01-01 00:00:00